Following the accomplishments of PD-1 and CTLA-4 inhibitors, others targeting TIGIT, Tim-3, Lag3 and NKG2A are currently being explored in some solid tumors in various pre-clinical and clinical trials, in order to promote effective anti-tumor immunity with clinical benefits. Here, KLRC1 is linked to neoplasm.